Season 7 · Episode 50
S7 Ep50: FDA Approval Insights: Durvalumab Plus Tremelimumab in HCC
OncLive® On Air · OncLive® On Air
November 24, 202218m 32s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Abou-Alfa discusses the FDA approval of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma, the regimen’s unique mechanism of action, and the importance of expanding global access to this combination.